Page 2015.

Methods	Double‐blind placebo‐controlled randomized trial (see Page 2013), this study is the follow‐up after 6 months Setting: general ICU Country: UK Groups: haloperidol vs. placebo Period: not stated
Participants	Sample size: 142 Included Not stated Excluded Not stated Missing: not stated how many, however data were imputed
Interventions	Interventions: receive haloperidol 2.5 mg every 8 hours Control: 0.9% saline placebo intravenously every 8 hours until delirium free for 48 hours, discharge or death.
Outcomes	Primary Score on telephone interview of cognitive status (TICS‐M) Secondary Score on EQ‐5D (resource use and quality of life ‐ QALY) Number of survival days Measured by: TICS‐M and EQ‐5D Adverse events: not stated
Notes	Conclusion: TISC‐M scores assessed in 57 survivors (69%) were below normal, however not different between groups. Authors concluded: delirium adversely impacts cognitive function and QoL following critical illness. Funding: not stated Conflict of interest: not stated Study number: not stated, but referred to as HOPE‐ICU trial (ISRCTN83567338) This health evaluation and cost‐effectiveness originated from Page 2015 study data (see previous). Contact with authors: authors were emailed 12 September 2016, asking for further results and full paper reporting — awaiting response.